Blood protein predicts Alzheimer's risk up to 13 years in advance

A new blood biomarker now quantifies individual risk of Alzheimer's progression in cognitively healthy adults with striking precision. Analysis of 2,684 participants followed for up to 13.5 years reveals that those with very high p-tau217 levels—more than 2.5 standard deviations above the mean—face a 38% absolute risk of cognitive impairment within 5 years, with higher cumulative risk over 10 years. P-tau217 is a phosphorylated variant of tau protein whose hyperphosphorylation triggers pathological aggregation and chronic brain inflammation, accelerating neurodegeneration. Though the medical establishment has hesitated to act on predictive blood tests lacking obvious pharmaceutical follow-up, early detection now justifies aggressive lifestyle optimization: sleep, diet, exercise, and systemic inflammation control become urgent. Longevity-focused readers should view this differently: a simple blood test can reveal whether neurodegeneration is already advancing in your brain, enabling intervention years before symptoms emerge—shifting Alzheimer's prevention from reactive to proactive.